

Ref: FOI/GS/ID 7303

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

23 May 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to advanced hepatocellular carcinoma (Stage 3b and 4).

You asked:

Q1. How many patients have been diagnosed with advanced hepatocellular carcinoma (Stage 3b and 4) in the last 6 months?

Q2. How many hepatocellular carcinoma patients (any stage) have been treated in the last 6 months with the following treatments:

- a. Lenvatinib*
- b. Sorafenib*
- c. Regorafenib*
- d. Atezolizumab + Bevacizumab*

Q3. In the last 6 months, how many patients has your trust treated (for any condition) with the following treatments:

- a. Avatrombopag*
- b. Eltrombopag*
- c. Fostamatinib*
- d. Romiplostim*

Q4. In the last 6 months, how many patients has your trust treated for Immune thrombocytopenia (ICD10 code D69.3) ONLY with the following treatments:

- a. Avatrombopag*
- b. Mycophenolate mofetil*
- c. Rituximab*
- d. Surgery (splenectomy)*

Q5. Does your trust participate in any clinical trials for the treatment of hepatocellular carcinoma? If so, can you please provide the name of each trial and the number of patients taking part.

Trust response:

Q1. No patients from 01/09/21 - 28/02/22.

Q2.

a. 0

b. 2

c. 0

d. 0

Q3. Data from Oct 2021 to March 2022

a. 0

b. 47

c. 0

d. 23

Q4. Data from Oct 2021 to March 2022

a. The Trust does not use this drug.

b. The Trust does not have the details for this.

c. 0

d. The Trust does not have the details for this.

Q5. Not currently.